| Institution: | 1. Institute of Medical Epidemiology, Biometrics and Informatics, Medical Faculty of the Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany;2. Department of Internal Medicine III - Cardiology, Mid-German Heart Center, University Hospital Halle (Saale), Halle, Germany;3. Department of Cardiac Surgery, Mid-German Heart Center, University Hospital Halle (Saale), Halle, Germany;4. Division of Cancer Epidemiology, German Cancer Research Centre, Heidelberg, Germany;1. Department of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico;2. Department of Nephrology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico;3. Department of Molecular Biology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico;1. Department of Medicine, University of Verona, Verona, Italy;2. Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy;3. Department of Medicine, Section of Geriatrics, Healthy Aging Center Verona, Italy;4. Section of Geriatrics, Department of Medicine, Treviso, Italy;1. Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;2. Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China |
| Abstract: | Background and aimsThe visceral adiposity index (VAI) has been recently established as a measure of visceral fat distribution and is shown to be associated with a wide range of adverse health events. However, the precise associations between the VAI score and all-cause and cause-specific mortalities in the general population remain undetermined.Methods and resultsIn this large-scale prospective epidemiological study, 357,457 participants (aged 38–73 years) were selected from the UK Biobank. We used Cox competing risk regression models to estimate the association between the VAI score and all-cause, cardiovascular disease (CVD), cancer, and other mortalities. The VAI score was significantly correlated with an increased risk of all-cause mortality (hazard ratio HR], 1.200; 95% confidence interval CI], 1.148–1.255; P < 0.0001), cancer mortality (HR, 1.224; 95% CI, 1.150–1.303; P < 0.0001), CVD mortality (HR, 1.459; 95% CI, 1.148–1.255; P < 0.0001), and other mortalities (HR, 1.200; 95% CI, 1.148–1.255; P < 0.0001) after adjusting for a series of confounders. In addition, the subgroup analyses showed that HRs were significantly higher in participants who were male, aged below 65 years, and body mass index less than 25.ConclusionIn summary, VAI was positively associated with an increased risk of all-cause and cause-specific mortalities in a nationwide, well-characterised population identified in a UK Biobank. The VAI score might be a complementary traditional predictive indicator for evaluating the risk of adverse health events in the population of Western adults aged 38 years and older. |
